NPHC Nutra Pharma Corp (CE)

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
[ ] Form 3 Holdings Reported
[X] Form 4 Transactions Reported UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

                                                                                  
OMB APPROVAL
OMB Number: 3235-0362
Estimated average burden
hours per response... 1.0                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * DEITSCH RIK J	2. Issuer Name and Ticker or Trading Symbol NUTRA PHARMA CORP [NPHC]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) President, CEO
(Last)          (First)          (Middle) 1537 NW 65TH AVENUE	3. Statement for Issuer's Fiscal Year Ended (MM/DD/YYYY) 11/15/2021
(Street) PLANTATION, FL 33313 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form Filed by One Reporting Person ___ Form Filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				Amount	(A) or (D)	Price
Common Stock							43298859	D
Series B Preferred Stock (1)	11/15/2021		P4	3000000	A	(2)	3000000	D
Series B Preferred Stock (1)	11/15/2021		P4	9000000	A	(3)	12000000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (MM/DD/YYYY)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:
(1)	Series B preferred stock have no right of conversion to shares of common stock. Each share of Series B preferred stock is entitled to vote with the Corporation's common stock as a single class on all matters submitted to common stock holders to vote. Each share of Series B Preferred Stock is entitled to one thousand votes per share.
(2)	3,000,000 shares of Series A Preferred Stock held by Mr. Deitsch were exchanged for an equal number of Series B Preferred Stock of the Company pursuant to a share exchange agreement between Rik Deitsch and the Company.
(3)	9,000,000 shares of Series B Preferred Stock were issued in satisfaction of corporate debt owed by the Company to Mr. Deitsch pursuant to a resolution adopted by the board of directors of the Company.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
DEITSCH RIK J 1537 NW 65TH AVENUE PLANTATION, FL 33313	X		President, CEO

Signatures
/s/ Rik J. Deitsch		1/14/2022
**Signature of Reporting Person		Date